DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorAstraZeneca

About this trial

This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records. Convenience sample, with an estimated inclusion of 200 patients treated in seven participating centers.

Eligible tumors for this project will be from patients with advanced (unresectable or metastatic) non-small cell lung carcinoma, who will start first-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026). Patients must be over 18 years old and data must be available in electronic medical records.

Medical records will be assessed to confirm patients' eligibility. Patients with localized disease amenable to local treatment, non-epithelial histology, small cell carcinoma and neuroendocrine tumor will not be eligible.

A survey will be designed targeting thoracic and generalist medical oncologists, aiming to understand the factors guiding the choice of first-line treatment regimens and to compare these insights with real-world data. The survey will be directed to Brazil, with an estimated of 200 filled files.

Eligibility criteria

Qualifiers

Advanced (unresectable or metastatic) non-small cell lung carcinoma

First-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026)

> 18 years old

Data available in electronic medical records.

Disqualifiers

Localized disease amenable to local treatment

Non-epithelial histology

Small cell carcinoma

Neuroendocrine tumor

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

7
Research Site Recife Brazil
Research Site Rio de Janeiro Brazil
Research Site Rio de Janeiro Brazil
Research Site Salvador Brazil

Sponsors and collaborators

AstraZeneca

Lead sponsor